Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-8-17
pubmed:abstractText
This study evaluates the relationship of six polymorphisms found in the CHRNA3, DRD2 and COMT genes with nicotine dependence, the ability to quit smoking and the occurrence of withdrawal symptoms after short-term use of nicotine patch in hospitalized patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1744-8042
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1053-63
pubmed:dateRevised
2011-7-15
pubmed:meshHeading
pubmed-meshheading:20712524-Adolescent, pubmed-meshheading:20712524-Adult, pubmed-meshheading:20712524-Aged, pubmed-meshheading:20712524-Aged, 80 and over, pubmed-meshheading:20712524-Catechol O-Methyltransferase, pubmed-meshheading:20712524-Double-Blind Method, pubmed-meshheading:20712524-Female, pubmed-meshheading:20712524-Hospitalization, pubmed-meshheading:20712524-Humans, pubmed-meshheading:20712524-Male, pubmed-meshheading:20712524-Middle Aged, pubmed-meshheading:20712524-Nicotine, pubmed-meshheading:20712524-Polymorphism, Genetic, pubmed-meshheading:20712524-Questionnaires, pubmed-meshheading:20712524-Receptors, Dopamine D2, pubmed-meshheading:20712524-Receptors, Nicotinic, pubmed-meshheading:20712524-Smoking Cessation, pubmed-meshheading:20712524-Substance Withdrawal Syndrome, pubmed-meshheading:20712524-Tobacco Use Disorder, pubmed-meshheading:20712524-Transdermal Patch, pubmed-meshheading:20712524-Treatment Outcome, pubmed-meshheading:20712524-Young Adult
pubmed:year
2010
pubmed:articleTitle
Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients.
pubmed:affiliation
Department of Basic Medical Sciences, Ghent University, Proeftuinstraat 86, Gent, Belgium.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase III